Targeting gene-virotherapy for cancer

Acta Biochimica et Biophysica Sinica

Volumn 37, Issue 9, 2005, Pages 581-587

  Liu, Xin Yuan ^a,b   Gu, Jing Fa ^a   Shi, Wen Fang ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

Cancer; Gene; Targeting gene virus; Targeting viral vector; Therapy

Indexed keywords

ADENOVIRIDAE;

APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; DIABLO PROTEIN, HUMAN; DIABLO PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN; PROTEIN; SIGNAL PEPTIDE; SUPEROXIDE DISMUTASE; TNFSF10 PROTEIN, HUMAN; TNFSF10 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRUS; ANIMAL; DRUG ANTAGONISM; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; METHODOLOGY; MOUSE; NEOPLASM; PHYSIOLOGY; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE; VIRUS;

ADENOVIRIDAE; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; GENE TARGETING; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MITOCHONDRIAL PROTEINS; NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTEINS; SUPEROXIDE DISMUTASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; VIRUSES;

EID: 26944497271     PISSN: 16729145     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2005.00087.x     Document Type: Short Survey

References (31)

1. Khuri F, Nemunaitis J, Ganly I, Arseneau J, Tannock I, Romel L, Gore M et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6: 879-885
2. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000, 7: 859-866
3. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001, 61: 7464-7472
4. Markert J, Medlock M, Rabkin S, Gillespie G, Todo T, Hunter W, Palmer C et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000, 7: 867-874
5. Liu XY. A new strategy for cancer therapy: Targeting gene-virotherapy of cancer. Chinese J Cancer Biotherapy 2001, 8: 1
6. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274: 373-376
7. Kao C, Yew P, Berk A. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 1990, 179: 806-814
8. Yew P, Berk A. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992, 357: 82-85
9. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ et al. An armed oncolytic adenovirus system, zd55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003, 13: 481-489
10. Antonio Chiocca E. Oncolytic viruses. Nat Rev Cancer 2002, 2: 938-950
11. Post DE, van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003, 22: 2065-2072
12. Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: Dependence on El A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003, 63: 1490-1499
13. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000, 106: 763-771
14. Rodriguez R, Schuur E, Lim H, Henderson G, Simons J, Henderson D. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997, 57: 2559-2563
15. Komata T, Kanzawa T, Kondo Y, Kondo S. Telomerase as a therapeutic target for malignant gliomas. Oncogene 2002, 21: 656-663
16. Blackburn E. Structure and function of telomeres. Nature 1991, 350: 569-573
17. Meyerson M, Counter C, Eaton E, Ellisen L, Steiner P, Caddle S, Ziaugra L et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90: 785-795
18. Shay J. Telomerase in human development and cancer. J Cell Physiol 1997, 173: 266-270
19. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999, 59: 826-830
20. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999, 59: 551-557
21. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000, 60: 5359-5364
22. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002, 21: 8020-8028
23. Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z, Qian C et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 2004, 23: 457-464
24. Zhang Q, Nie M, Sham J, Su C, Xue H, Chua D, Wang W et al. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res 2004, 64: 5390-5397
25. Qiu S, Ruan H, Pei Z, Hu B, Lan P, Wang J, Zhang Z et al. Combination of targeting gene-virotherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma. J Interferon Cytokine Res 2004, 24: 219-230
26. Liu X, Qiu S, Zou W, Pei Z, Gu J, Luo C, Ruan H et al. Effective gene-virotherapy for complete eradication of tumor mediated by combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005, 11: 531-541
27. Zhang Z, Zou W, Wang J, Gu J, Dang Y, Li B, Zhao L et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther 2005, 11: 553-562
28. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004, 39: 1371-1381
29. Tang YX, Chen Y, Gu JF, Qi R, Zou WG. Killing effect of Ad-TERT-TRAIL on tumor cell line. Aizheng 2005, 24: 536-542
30. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, Wang Y et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005, 16: 1-14
31. Zhang YH, Gu JF, Zhao LL, Wang JH, Wang YG, He LF, Zou WG et al. Complete elimination of xenograft SW620 cancer by combined tumor-targeting MnSOD and Trail genes. Cancer Res 2005, accepted